Galectin Therapeutics

(NASDAQ) GALT

Current Price$2.27

Market Cap$149.43M

Since IPO (2002)-81%

5 Year-49%

1 Year+66%

1 Month-19%

Galectin Therapeutics Financials at a Glance

Market Cap

$149.43M

Revenue (TTM)

$0.00

Net Income (TTM)

$30.84M

EPS (TTM)

$-0.48

P/E Ratio

-4.68

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Price

$2.27

Volume

301,564.073

Open

$2.28

Price

$2.27

Volume

301,564.073

Open

$2.28

Previous Close

$2.27

Daily Range

$2.23 - $2.35

52-Week Range

$1.21 - $7.13

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Price

$2.27

Volume

301,564.073

Open

$2.28

Previous Close

$2.27

Daily Range

$2.23 - $2.35

52-Week Range

$1.21 - $7.13

GALT News

Why Plug Power, Varonis Systems, and Galectin Therapeutics Are Today's 3 Best Stocks

Sean WilliamsMar 25, 2014

Why Galectin Therapeutics, Inc. Shares Soared

Sean WilliamsMar 25, 2014

Page 1

GALT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Galectin Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Joel Lewis, CPA

Website

www.galectintherapeutics.com

Headquarters

Norcross, GA 30071, US

GALT Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

Return on Capital

-2%

Return on Assets

-2%

Earnings Yield

-21.37%

Dividend Yield

0.00%

Payout Ratio

-0.20%

Stock Overview

Market Cap

$149.43M

Shares Outstanding

65.83M

Volume

301.56K

Avg. Volume

317.30K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$20.09M

EBITDA

$23.45M

Operating Cash Flow

$23.88M

Capital Expenditure

$0.00

Free Cash Flow

$23.88M

Cash & ST Invst.

$17.72M

Total Debt

$133.74M

Galectin Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$12.00K

+220.0%

Gross Margin

0.00%

N/A

Market Cap

$149.43M

N/A

Market Cap/Employee

$9.96M

N/A

Employees

N/A

Net Income

$5.50M

+54.0%

EBITDA

$3.52M

+65.6%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$116.02M

-27.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$133.74M

+57.1%

Short Term Debt

$22.00K

-99.9%

Return on Assets

-1.58%

N/A

Return on Invested Capital

-1.75%

N/A

Free Cash Flow

$6.04M

+52.8%

Operating Cash Flow

$6.04M

+52.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

QSIQuantum-Si incorporated

QSIQuantum-Si incorporated$0.98+13.39%

ALTAltimmune, Inc.

ALTAltimmune, Inc.$2.60-1.14%

DMACDiaMedica Therapeutics Inc.

DMACDiaMedica Therapeutics Inc.$6.05+1.51%

ENGNenGene Holdings Inc.

ENGNenGene Holdings Inc.$7.27+3.27%

RCKTRocket Pharmaceuticals, Inc.

RCKTRocket Pharmaceuticals, Inc.$3.48-0.00%

AURAAura Biosciences, Inc.

AURAAura Biosciences, Inc.$7.05+4.75%

IMABI-Mab

IMABI-Mab$2.88-0.69%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$12.47+0.05%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$63.54+0.03%

INTCIntel

INTCIntel$94.48-0.00%

NOKNokia

NOKNokia$12.91+0.04%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$51.65-0.03%

QQQInvesco QQQ Trust

QQQInvesco QQQ Trust$667.74+0.01%

AMDAdvanced Micro Devices

AMDAdvanced Micro Devices$354.49+0.05%

Questions About GALT

What is the current price of Galectin Therapeutics?

Galectin Therapeutics is trading at $2.27 per share.

What is the 52-week range for Galectin Therapeutics?

Over the past 52 weeks, Galectin Therapeutics has traded between $1.21 and $7.13.

How much debt does Galectin Therapeutics have?

As of the most recent reporting period, Galectin Therapeutics reported total debt of $133.76M.

How much cash does Galectin Therapeutics have on hand?

Galectin Therapeutics reported $17.72M in cash and cash equivalents in its most recent financial results.

What is Galectin Therapeutics’s dividend yield?

Galectin Therapeutics does not currently have a dividend yield.

Galectin Therapeutics

Galectin Therapeutics Financials at a Glance

GALT News

Galectin Beats Q2 Loss Estimates

3 Stocks That Could Double Your Money

Why Galectin Therapeutics Stock Bolted Higher Today

2 Clinical-Stage Biotech Stocks That Could Soar Next Week

3 NASH Stocks That Could Soar in the Second Half of 2018

Why Galectin Therapeutics Inc. Shares Jumped

Why Plug Power, Varonis Systems, and Galectin Therapeutics Are Today's 3 Best Stocks

Why Galectin Therapeutics, Inc. Shares Soared

GALT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Galectin Therapeutics

GALT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Galectin Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About GALT

What is the current price of Galectin Therapeutics?

What is the 52-week range for Galectin Therapeutics?

How much debt does Galectin Therapeutics have?

How much cash does Galectin Therapeutics have on hand?

What is Galectin Therapeutics’s dividend yield?

Premium Investing Services